Astex Pharmaceuticals, Inc. (ASTX)
-NasdaqGS 4.88 
0.35(7.73%) Jun 17, 4:00PM EDT
| Prev Close: | 4.53 |
|---|
| Open: | 4.64 |
|---|
| Bid: | 4.60 x 2100 |
|---|
| Ask: | 4.92 x 2000 |
|---|
| 1y Target Est: | 7.33 |
|---|
| Beta: | 1.48 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 4.61 - 4.92 |
|---|
| 52wk Range: | 2.00 - 6.95 |
|---|
| Volume: | 1,549,749 |
|---|
| Avg Vol (3m): | 1,692,790 |
|---|
| Market Cap: | 461.66M |
|---|
| P/E (ttm): | 101.67 |
|---|
| EPS (ttm): | 0.05 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Another Alzheimer's Disease Failureat Motley Fool(Sun, Jun 16)
- Boeing Plans Next 787, Consolidated Edison Gets Upgraded, and 3 More Hot Stocksat Wall St. Cheat Sheet(Fri, Jun 14)
- ASTEX PHARMACEUTICALS, INC Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersEDGAR Online(Fri, Jun 14)
- Astex Pharmaceuticals Announces Presentation of Updated Results of SGI-110-01 Study in Patients With Intermediate or High Risk Relapsed or Refractory Myelodysplastic Syndromes at the European Hematology AssociationGlobeNewswire(Fri, Jun 14)
- Put seller believes Astex will hold firmoptionMONSTER(Wed, Jun 12)
- 5 Best Biotechs of 2013at Motley Fool(Thu, May 30)
- Astex Pharmaceuticals to Present at Jefferies Global Healthcare ConferenceGlobeNewswire(Wed, May 29)
- Astex Pharmaceuticals' CEO Presents at UBS Global Healthcare Conference (Transcript)at Seeking Alpha(Mon, May 20)
- ASTEX PHARMACEUTICALS, INC FinancialsEDGAR Online Financials(Fri, May 17)
- Astex Pharmaceuticals to Present at UBS Global Healthcare ConferenceGlobeNewswire(Tue, May 14)
- Short Interest Moves 16% Higher For ASTXat TheStreet(Fri, May 10)
- ASTEX PHARMACEUTICALS, INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, May 10)
- 3 Horrendous Health-Care Stocks This Weekat Motley Fool(Sat, May 4)
- Astex Pharmaceuticals Inc Stock Downgraded (ASTX)at TheStreet(Wed, May 1)
- Expert Analyst Ian Somaiya Discusses the Decline in European Drug Pricing with The Wall Street Transcript; Models a 1% to 2% Annual Decline in Price for Companies That Sell OverseasWall Street Transcript(Tue, Apr 30)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 5.15 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.28 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.06 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Astex Pharmaceuticals, Inc. engages in the discovery and development of small molecule therapeutics with a focus on oncology and hematology using its fragment-based drug discovery platform, Pyramid.
View More